Apolipoprotein CIII: a link between hypertriglyceridemia and vascular dysfunction?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism.Diabetes care · 2011
   Trial
2. Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.Current atherosclerosis reports · 2026
   Review
3. Characterization of Apolipoprotein C3 (Apo C3) LNA/DNA Impurities and Degradation Products by LC-MS/MS.The AAPS journal · 2017
   Article
4. Key differences between apoC-III regulation and expression in intestine and liver.Biochemical and biophysical research communications · 2017
   Article
5. RNA-seq analysis provide new insights into mapk signaling of apolipoproteinciii-induced inflammation in porcine vascular endothelial cells.Cell cycle (Georgetown, Tex.) · 2017
   Article
6. Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.Biology open · 2015
   Article
7. Development of a sensitive ELISA to quantify apolipoprotein CIII in nonhuman primate serum.Journal of lipid research · 2011
   Article

Corrections and comments

• Comment on
  Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as